ACACIA Study Is Evaluating Two Long-Acting Broadly Neutralizing Antibodies Given at HIV Treatment Initiation
ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of the ACACIA study (Antiretrovirals Combined with Antibodies for HIV-1 Cure in Africa), also known as A5417. ACACIA is a phase 2, double-blind, randomized study evaluating the safety and virologic and immunologic effects of the two long-acting broadly neutralizing antibodies (bNAbs) 3BNC117-LS and 10-1074-LS when given at the start of antiretroviral therapy (ART) to adults living with HIV in four African countries.